WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
56.05
+2.55 (4.77%)
Sep 30, 2026, 4:08 PM HKT

WuXi Biologics Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
5,0094,9083,3563,4004,4203,388
Depreciation & Amortization
1,5311,4481,4371,169800.67481.78
Other Amortization
29.9829.9824.43-73.8832.3690.49
Loss (Gain) From Sale of Assets
634.68634.68-0.463.4819.270.87
Loss (Gain) From Sale of Investments
-1,045-1,04591.72-13.83-379.44-665.44
Stock-Based Compensation
955.06955.061,2161,2741,234531.92
Provision & Write-off of Bad Debts
205.33205.33151.78319.97258.53156.67
Other Operating Activities
3,233935.66-258.43-514.84130.08409.82
Change in Accounts Receivable
-2,590-2,590161.93-1,038-1,500-1,441
Change in Inventory
6.396.39201.85442.46-498.12-783.19
Change in Accounts Payable
797.37797.37375.38-162.34-509.02741.85
Change in Unearned Revenue
410.38410.38-1,313-317.21,6331,071
Change in Other Net Operating Assets
-355.53-355.53-226.69178.41-100.14-551.77
Operating Cash Flow
8,8216,3415,2174,6685,5423,431
Operating Cash Flow Growth
54.17%21.54%11.77%-15.77%61.51%82.39%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-4,542-3,685-3,930-4,046-5,868-6,508
Sale of Property, Plant & Equipment
1,2534,17787.33196.8620.1380.86
Cash Acquisitions
-1,196----131.49-2,181
Sale (Purchase) of Intangibles
-50.6-50.6--10--
Investment in Securities
-579.32-3,952-387.97596.39-253.24-1,428
Other Investing Activities
414.51423.07288.5634.07324.74433.9
Investing Cash Flow
-4,687-3,087-3,942-3,228-5,908-9,602

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-1,1221,1291,0972,389675.28
Total Debt Issued
255.231,1221,1291,0972,389675.28
Long-Term Debt Repaid
--2,901-818.68-1,916-2,684-822.11
Lease Payments
-165.85-149.84-180.14-113.7-121.09-93.84
Total Debt Repaid
-2,852-2,901-818.68-1,916-2,684-822.11
Net Debt Issued (Repaid)
-2,597-1,779309.96-818.45-295.02-146.83
Issuance of Common Stock
149.08163.0719.3926.1636.1811,035
Repurchase of Common Stock
-1,566-1,577-1,766-916.92-2,804-2,517
Other Financing Activities
824.691,029-1,3143,670471.7-161.91
Financing Cash Flow
-3,190-2,164-2,7501,961-2,5928,209

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-433.75-155.2183.98-125.99350.11-131.5
Net Cash Flow
510.99934.6-1,3913,275-2,6081,908

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
4,2792,6561,288622.14-326.72-3,077
Free Cash Flow Growth
143.25%106.25%106.97%---
Free Cash Flow Margin
18.12%12.19%6.89%3.65%-2.14%-29.90%
Free Cash Flow Per Share
1.020.640.300.14-0.07-0.70
Levered Free Cash Flow
2,4194,284-2,296-320.31-594.39-3,720
Unlevered Free Cash Flow
2,4854,373-2,198-221.25-554.16-3,696
Free Cash Flow After Leases
4,1142,5061,107508.44-447.8-3,170

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
117.84159.57200.61217.28108.2483.2
Cash Income Tax Paid
1,4001,4001,092782.53585.66349.99
Change in Working Capital
-1,731-1,731-800.5-896.35-974.47-963.33